You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Strattera Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Strattera patents expire, and when can generic versions of Strattera launch?

Strattera is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in STRATTERA is atomoxetine hydrochloride. There are sixteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the atomoxetine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Strattera

A generic version of Strattera was approved as atomoxetine hydrochloride by ZYDUS PHARMS USA INC on September 16th, 2010.

  Try a Trial

Drug patent expirations by year for Strattera
Drug Prices for Strattera

See drug prices for Strattera

Drug Sales Revenue Trends for Strattera

See drug sales revenues for Strattera

Recent Clinical Trials for Strattera

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Brown UniversityPhase 2
National Institute on Alcohol Abuse and Alcoholism (NIAAA)Phase 2
Takeda Development Center Americas, Inc.Phase 4

See all Strattera clinical trials

Pharmacology for Strattera
Paragraph IV (Patent) Challenges for STRATTERA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
STRATTERA Capsules atomoxetine hydrochloride 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg 021411 10 2007-05-29

US Patents and Regulatory Information for Strattera

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-001 Nov 26, 2002 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-007 Feb 14, 2005 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-004 Nov 26, 2002 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-008 Feb 14, 2005 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-002 Nov 26, 2002 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-003 Nov 26, 2002 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Strattera

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-001 Nov 26, 2002 ⤷  Try a Trial ⤷  Try a Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-006 Nov 26, 2002 ⤷  Try a Trial ⤷  Try a Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-008 Feb 14, 2005 ⤷  Try a Trial ⤷  Try a Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-002 Nov 26, 2002 ⤷  Try a Trial ⤷  Try a Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-005 Nov 26, 2002 ⤷  Try a Trial ⤷  Try a Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-004 Nov 26, 2002 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for Strattera

See the table below for patents covering Strattera around the world.

Country Patent Number Title Estimated Expiration
Japan H10512262 ⤷  Try a Trial
Mexico 9705117 USO DE TOMOXETINA PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL DESORDEN DE DEFICIT DE LA ATENCION/HIPERACTIVIDAD. (TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER.) ⤷  Try a Trial
Finland 119354 ⤷  Try a Trial
Hungary 9801283 ⤷  Try a Trial
Finland 972922 ⤷  Try a Trial
Russian Federation 2163802 METHOD FOR TREATING ATTENTION DEFICIENCY/HYPERACTIVITY ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for Strattera

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0721777 C00721777/01 Switzerland ⤷  Try a Trial PRODUCT NAME: ATOMOXETIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58245 08.04.2009
0721777 91238 Luxembourg ⤷  Try a Trial 91238, EXPIRES: 20190527
0721777 300180 Netherlands ⤷  Try a Trial 300180, 20160109, EXPIRES: 20190526
0721777 PA2006006 Lithuania ⤷  Try a Trial PRODUCT NAME: ATOMOXETINUM HYDROCHLORICUM; REG. NO/DATE: PL 00006/0374-0379 20040527
0721777 SZ 18/2006 Austria ⤷  Try a Trial PRODUCT NAME: ATOMOXETIN, GEGEBENENFALLS IN FORM EINES SALZES, WIE ALS HYDROCHLORID
0721777 CA 2006 00030 Denmark ⤷  Try a Trial PRODUCT NAME: ATOMOXETIN, EVENTUELT I FORM AF ET SALT DERAF, SASOM HYDROCHLORIDET
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.